Context Given the highly variable behavior and clinical course of prostate cancer (PCa) and
the multiple available treatment options, a personalized approach to oncologic risk …

The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate
cancer has hampered progress in understanding disease pathogenesis and therapy …

The ETS family of proteins consists of 28 transcription factors, many of which play critical
roles in both normal tissue development and homeostasis and have been implicated in …

Prostate cancer represents a substantial clinical challenge because it is difficult to predict
outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 …

The pathogenic mechanisms of prostate cancer (PCa) remain to be defined. In this study, we
utilized the Robust Rank Aggregation (RRA) method to integrate 10 eligible PCa microarray …

Background The clinical course of prostate cancer (PCa) is highly variable, demanding an
individualized approach to therapy. Overtreatment of indolent PCa cases, which likely do not …

Despite a multitude of p53 immunohistochemistry (IHC) studies, data on the combined effect
of nuclear p53 protein accumulation and TP53 genomic inactivation are lacking for prostate …

Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures
for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its …

Background Genomic analyses of hundreds of prostate tumors have defined a diverse
landscape of mutations and genome rearrangements, but the transcriptomic effect of this …

Prostate cancers are highly prevalent in the developed world, with inheritable risk
contributing appreciably to tumour development. Genomic heterogeneity within individual …